Deep TMS treatment is FDA approved for the treatment of Depression, Smoking Cessation, and other conditions. We believe it can be valuable to combine with addiction treatment, particularly to target commonly co-occuring diagnoses.

Deep TMS involves 36 sessions over 8-10 weeks, while the condensed alternative protocol, Accelerated TMS, involves 50 sessions over 5 consecutive days. A version of Accelerated TMS, SAINT TMS, which incorporates brain imaging via MRI, was FDA approved in 2021. While Deep TMS is often covered by insurance, Accelerated TMS is not.

We believe both protocols are clinically valuable, and selection depends on a patients' time and financial needs.

GLP-1s are FDA-approved medications for Diabetes and Obesity, and are increasingly showing promise for addiction treatment in clinical trials and in the community.  

GLP-1s appear to impact one's feelings of craving and sense of reward, which can be powerful for training patients to manage craving and build resilience against triggers. GLP-1s also impact one's weight and metabolic health, requiring careful screening and safety monitoring.

We believe GLP-1s are highly promising for addiction treatment, when combined with careful safety monitoring and a therapy protocol to leverage its effects appropriately.

MDMA-Assisted Therapy (MDMA-AT) is an experimental treatment which has been researched mostly for PTSD treatment. MDMA-AT has shown promise for addiction treatment, and may be particularly helpful when trauma underlies or coincides with the addiction.  

MDMA is a drug with some properties similar to that of psychedelics and supports feelings of empathy and connection. By leveraging these properties, MDMA-AT may allow patients to get to the ‘root cause’ of their trauma more easily, accelerating the impact of talk therapy.  

We view MDMA-AT as a powerful treatment requiring highly specialized therapists to support before, during and around the sessions.

Psilocybin Therapy is an experimental treatment that has been mostly studied for Depression and Alcohol Use Disorder. While it is still being researched, it is legal and available in Colorado and Oregon through state programs.

Psilocybin is a naturally occuring psychedelic that appears to temporarily impact certain brain network activities and the brain's rate of learning. This may allow for a ‘re-wiring’ of learned perspectives or habits, which can support addiction treatment.

Psilocybin creates altered states of consciousness and can be a powerful tool. We believe it requires safe, compassionate, and specialized clinicians and settings to support.

Focused Ultrasound (FUS) is showing great promise for Parkinsons and Essential Tremor by targeting specific brain activity. FUS is neuromodulation tools, simialr to treatments like deep TMS, which is used in addiction treatment. The early research in a limited set of patients is highly encouraging and is worth accelerarting.

We believe this type of precise neuromodulation can have great impact on addiction, and are focused on accelerating its application and use in addiction treatment.

Ketamine emerged as a tool in Anesthesiology, but was later studied for mental health treatment, including Depression and Alcohol Use Disorder. In 2019, a form of ketamine, esketamine (Spravato) was FDA-approved for Treatment Resistant Depression, and Spravato is covered by some insurance.

In specific doses, ketamine shares some properties as psychedelics, altering patients' perspectives, which can be supportive in treatment when combined with therapy.

Ketamine has some addictive properties, so we advise to exercise caution, and only receive ketamine treatment in trusted healthcare settings and in conjunction with therapy in order to maximize its clinical benefits.